Personal information

antimicrobial pharmacology, population pharmacokinetics, pharmacodynamics, mechniastic modeling, translational modeling, antibiotics, anti-infectives, beta-lactam antibiotics, aminoglycosides, cystic fibrosis, S-ADAPT
United States

Activities

Employment (6)

University of Florida: Orlando, FL, US

2020-07-01 to present | Professor and Perry E. Foote Eminent Scholar Chair (Department of Pharmacotherapy and Translational Research)
Employment
Source: Self-asserted source
Jürgen Bulitta

University of Florida: Orlando, FL, US

2015-07-17 to 2020-06-30 | Associate Professor, Pre-eminence Position in Drug Discovery & Development (Department of Pharmacotherapy and Translational Research)
Employment
Source: Self-asserted source
Jürgen Bulitta

Monash Institute of Pharmaceutical Sciences: Parkville, VIC, AU

2011-08-01 to 2015-04-15 | Senior Research Fellow, ARC DECRA Fellow (2012-14), NHMRC Career Development Fellow (CDF level 2, 2015)
Employment
Source: Self-asserted source
Jürgen Bulitta

Ordway Research Institute: Albany, New York, US

2009-03-22 to 2011-07-15 | Senior Scientist
Employment
Source: Self-asserted source
Jürgen Bulitta

University at Buffalo - The State University of New York: Buffalo, NY, US

2006-08-15 to 2009-03-21 | Postdoctoral fellow (Pharmaceutical Sciences)
Employment
Source: Self-asserted source
Jürgen Bulitta

Institute for Biomedical and Pharmaceutical Research: Nürnberg, Bavaria, DE

1998-07-27 to 2007-08-09 | Scientific co-worker
Employment
Source: Self-asserted source
Jürgen Bulitta

Education and qualifications (2)

Julius-Maximilians-Universität Würzburg: Wurzburg, Bayern, DE

2003-11-01 to 2006-09-25 | PhD in chemistry (Pharmcokinetics / Pharmacodynamics) (Institute of Pharmacy & Food Chemistry)
Education
Source: Self-asserted source
Jürgen Bulitta

Friedrich-Alexander-University: Erlangen-Nürnberg, Bavaria, DE

1999-09-15 to 2003-10-03 | MSc in Chemistry (German Diplom Degree)
Education
Source: Self-asserted source
Jürgen Bulitta

Funding (21)

Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding

2018-08 to 2023-07 | Grant
National Institute of Allergy and Infectious Diseases (Bethesda, MD, US)
GRANT_NUMBER: R01AI136803
Source: Self-asserted source
Jürgen Bulitta

Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii

2017-11 to 2022-10 | Grant
National Institute of Allergy and Infectious Diseases (Bethesda, MD, US)
GRANT_NUMBER: R01AI130185
Source: Self-asserted source
Jürgen Bulitta

A Preclinical Mouse Model of Acinetobacter baumannii Infection For Antibacterial Development

2017-09 to 2020-09 | Contract
U.S. Food and Drug Administration (MD, MD, US)
GRANT_NUMBER: FDABAA-17-00123
Source: Self-asserted source
Jürgen Bulitta

Combating resistant Gram-negative bacterial superbugs via omics techniques

2017-06 to 2019-05 | Grant
University of Florida (FL, FL, US)
GRANT_NUMBER:

DRPD-ROF2017

Source: Self-asserted source
Jürgen Bulitta

Identification of antiviral therapies for the treatment of Zika virus using existing drugs

2017-02 to 2020-01 | Grant
Florida Department of Health (FL, FL, US)
GRANT_NUMBER: 7ZK30
Source: Self-asserted source
Jürgen Bulitta

Characterizing receptor binding of β-lactam antibiotics to combat resistant 'superbugs'

2017-01 to 2017-12 | Grant
College of Pharmacy (FL, FL, US)
GRANT_NUMBER:

COP PROSPER 2017

Source: Self-asserted source
Jürgen Bulitta

Comprehensive Evaluation of Formulation Effects on Metered Dose Inhaler Performance

2016-09 to 2018-08 | Grant
U.S. Food and Drug Administration (MD, MD, US)
GRANT_NUMBER: U01FD004943
Source: Self-asserted source
Jürgen Bulitta

Pharmacokinetic Comparison of Locally Acting Orally Inhaled Drug Products

2016-09 to 2018-03 | Contract
U.S. Food and Drug Administration (MD, MD, US)
GRANT_NUMBER: HHSF223201610099C
Source: Self-asserted source
Jürgen Bulitta

Targeting hypermutable ‘superbugs’ in chronic respiratory infections by optimised antibiotic combination dosage regimens

Source: Self-asserted source
Jürgen Bulitta via DimensionsWizard

Targeting bacterial ïsuperbugsÍ by innovative combination dosing strategies and new antibiotics

Source: Self-asserted source
Jürgen Bulitta via DimensionsWizard

Centre for REdefining antibiotic use to reDUce resistanCE and prolong the lives of antibiotics (REDUCE)

Source: Self-asserted source
Jürgen Bulitta via DimensionsWizard

Unravelling small RNA regulatory networks to target and control bacteria

Source: Self-asserted source
Jürgen Bulitta via DimensionsWizard

Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs

2014-03 to 2019-02 | Grant
National Institute of Allergy and Infectious Diseases (MD, MD, US)
GRANT_NUMBER: R01AI111990
Source: Self-asserted source
Jürgen Bulitta

Perturbation of the extracellular architecture to promote the absorption and lymphatic transport of biological macromolecules

Innovative dosing approaches to maximise bacterial killing and prevent resistance in septic critically ill patients.

Source: Self-asserted source
Jürgen Bulitta via DimensionsWizard

Optimising the efficacy and safety of fimasartan by translational, mechanism-based modelling

2014-01 to 2014-12 | Grant
National Research Foundation of Korea (Seoul, KR)
Source: Self-asserted source
Jürgen Bulitta

Study to investigate the sensitivity of pharmacokinetics in detecting differences in physicochemical properties of the active in suspension nasal products for local action

2013-09 to 2017-11 | Contract
U.S. Food and Drug Administration (MD, MD, US)
GRANT_NUMBER:

HHSF223201310220C

Source: Self-asserted source
Jürgen Bulitta
grade
Preferred source (of 2)‎

Combating bacterial ‘superbugs‘ by innovative dosing strategies that combine available antibiotics to prevent resistance

Source: Self-asserted source
Jürgen Bulitta via DimensionsWizard

Optimising the therapeutic efficacy of protein-based drugs against lymph-resident diseases

Source: Self-asserted source
Jürgen Bulitta via DimensionsWizard

Targeting bacterial superbugs: novel approaches for optimisation of antibiotic combinations and resistance prevention

Source: Self-asserted source
Jürgen Bulitta via DimensionsWizard

Targeting MDR hetero-resistant Gram-negatives: PK/PD for rational combinations

2008-07 to 2012-06 | Grant
National Institute of Allergy and Infectious Diseases (MD, MD, US)
GRANT_NUMBER: R01AI079330
Source: Self-asserted source
Jürgen Bulitta